Tejas Mehta, MD
Internal Medicine · Humble, TXNPI 1518956143
Payments from drug & device makers
Across 245 payments — averaging $490.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BD$85K
- GSK$30K
- Abbott$1K
- Biotronik Inc.$462
- AbbVie$438
- Novo Nordisk$433
- plus $2K from 35 others
What the payments were for
- Food & beverage$5,386100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BD | 2 | $84,875 |
| GSK | 32 | $30,426 |
| Abbott | 24 | $1,321 |
| Biotronik Inc. | 13 | $462 |
| AbbVie(2 entities) | 28 | $438 |
| Novo Nordisk | 27 | $433 |
| AstraZeneca | 15 | $220 |
| Amgen | 12 | $204 |
| Johnson & Johnson | 8 | $185 |
| Lilly USA, LLC | 10 | $175 |
| Abiomed | 3 | $146 |
| Medtronic | 2 | $139 |
| Pfizer | 7 | $127 |
| Boston Scientific | 6 | $125 |
| Sanofi-aventis U.S. LLC | 7 | $106 |
| Boehringer Ingelheim | 6 | $104 |
| Astellas Pharma US Inc | 6 | $99 |
| Esperion Therapeutics, Inc. | 4 | $71 |
| Exact Sciences | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| Amarin Pharma, Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Imperative Care, Inc | 1 | $35 |
| Convatec Inc. | 1 | $32 |
| Viatris Specialty LLC | 1 | $31 |
| Merck | 2 | $31 |
| Philips North America LLC | 2 | $29 |
| Novartis | 1 | $23 |
| Tolmar, Inc. | 1 | $21 |
| 3b Medical, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Vertiflex, Inc. | 1 | $12 |
| Cequr Corporation | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Confirm Rx$314
- Quartet CRT Lead$306
- AVEIR$171
- CoreValve Evolut$120
- Quadra Assura CRT Defibrillator$114
How this compares
$120,270 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 127 | $158,423 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $83,956 |
| RybelsusSemaglutide | 30 | $55,826 |
| EliquisApixaban | 36 | $51,687 |
| TrulicityDulaglutide | 31 | $38,454 |
| JanuviaSitagliptin Phosphate | 31 | $33,545 |
| FarxigaDapagliflozin Propanediol | 34 | $32,354 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $24,586 |
| JardianceEmpagliflozin | 18 | $22,990 |
| Aripiprazole | 52 | $11,913 |
| SynthroidLevothyroxine Sodium | 118 | $10,989 |
| MyrbetriqMirabegron | 11 | $10,633 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $7,145 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $6,879 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $6,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $433 | $214,249157 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $30,426 | $108,54289 claims |
| PfizerEliquis | $127 | $51,68736 claims |
| MerckJanuvia, Janumet Xr, Janumet | $31 | $43,13454 claims |
| Lilly USA, LLCTrulicity | $175 | $38,45431 claims |
| AstraZenecaFarxiga | $220 | $32,35434 claims |
| Boehringer IngelheimJardiance | $104 | $22,99018 claims |
| AbbVieSynthroid | $438 | $10,989118 claims |
| Astellas Pharma US IncMyrbetriq | $99 | $10,63311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Humble
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.